An 8-week Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of Oral Aliskiren 300 mg Once Daily Under Light Meal Versus Fasted Condition in Patients With Hypertension [Studio multicentrico, randomizzato, in aperto, della durata di 8 settimane per valutare efficacia e la sicurezza di aliskiren 300 mg al giorno somministrato per via orale dopo un pasto leggero rispetto alla somministrazione a digiuno in pazienti con ipertensione].
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01570686).
- 02 Apr 2012 Planned end date 1 Dec 2012 added as reported by ClinicalTrials.gov.